Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
US Department of Justice
Argus Health
Farmers Insurance
Accenture
Moodys
Harvard Business School
Medtronic
Merck

Generated: July 23, 2018

DrugPatentWatch Database Preview

Cyclobenzaprine hydrochloride - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for cyclobenzaprine hydrochloride and what is the scope of cyclobenzaprine hydrochloride patent protection?

Cyclobenzaprine hydrochloride
is the generic ingredient in three branded drugs marketed by Teva Pharms Intl, Twi Pharms Inc, Actavis Labs Fl Inc, Aurobindo Pharma, Frontida Biopharm, Invagen Pharms, Jubilant Cadista, Kvk Tech, Mylan Pharms Inc, Orit Labs Llc, Oxford Pharms, Pliva, Prinston Inc, Rubicon Res Pvt Ltd, Sandoz, Sun Pharm Inds Ltd, Upsher-smith Labs, Watson Labs, and Janssen Res And Dev, and is included in twenty NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Cyclobenzaprine hydrochloride has one patent family member in one country.

There are fifteen drug master file entries for cyclobenzaprine hydrochloride. Eighty-four suppliers are listed for this compound. There is one tentative approval for this compound.
Pharmacology for cyclobenzaprine hydrochloride
Synonyms for cyclobenzaprine hydrochloride
0VE05JYS2P
1-Propanamine, 3-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-, hydrochloride
1-Propanamine,d]cyclohepten-5-ylidene)-N,N-dimethyl-, hydrochloride
10,11.delta.-Amitriptyline hydrochloride
10,11delta-Amitriptyline hydrochloride
202C239
3-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)propyl(dimethyl)ammonium chloride
3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine hydrochloride
3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine Hydrochloride
3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine hydrochloride
3-(dibenzo[2,1-b:1',2'-e][7]annulen-11-ylidene)-N,N-dimethylpropan-1-amine;hydrochloride
303-53-7 (Parent)
5-(3-Dimethylaminopropylidene)-5H-dibenzo-(a,d)cycloheptene hydrochloride
5-(3-Dimethylaminopropylidene)dibenzo[a,e]cycloheptatriene hydrochloride
5-[3-(Dimethylamino)propylidene]-5H-dibenzo-[a,d]cycloheptene hydrochloride
5H-Dibenzo(a,d)cycloheptene-delta(sup 5)-gamma-propylamine, N,N-dimethyl-, hydrochloride
5H-Dibenzo(a,d)cycloheptene-delta5,gamma-propylamine, N,N-dimethyl-, hydrochloride
5H-Dibenzo(a,d)cycloheptene-delta5,gamma-propylamine, N,N-dimethyl-, hydrochloride (8CI)
5H-Dibenzo[a, N,N-dimethyl-, hydrochloride
5H-Dibenzo[a,.gamma.-propylamine, N,N-dimethyl-, hydrochloride
6202-23-9
AC-1916
AC1L2KN5
ACT06294
AK115687
AKOS015906329
Amrix
AN-14454
AS-15745
BCP9000565
C 4542
C-19294
C20H21N.HCl
CAS-6202-23-9
CC-26027
CCG-39312
CHEBI:3997
CHEMBL1200636
Cloben
CS-2981
CTK8F8847
Cyben
Cyclobenzaprine (hydrochloride)
Cyclobenzaprine HCL
Cyclobenzaprine hydrochloride (USP)
Cyclobenzaprine hydrochloride [USAN:USP]
Cyclobenzaprine hydrochloride [USAN]
Cyclobenzaprine Hydrochloride 1.0 mg/ml in Methanol (as free base)
Cyclobenzaprine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Cyclobenzaprine very low dose
CYCLOBENZAPRINEHCL
Cycloflex
D00772
D0NN8N
DIMETHYL(3-{TRICYCLO[9.4.0.0(3),?]PENTADECA-1(15),3,5,7,9,11,13-HEPTAEN-2-YLIDENE}PROPYL)AMINE HYDROCHLORIDE
DR001318
DSSTox_CID_25105
DSSTox_GSID_45105
DSSTox_RID_80672
DTXSID2045105
EINECS 228-264-4
EU-0100303
EUR-1002
Flexeril
Flexeril (TN)
Flexiban
FT-0603166
HMS1569I12
HMS1922I11
HY-B0740
KB-76226
LP00303
LS-60768
M-1230
MFCD00079039
Miosan
MK 130 hydrochloride
MK-130
MK-130 [AS THE BASE]
MLS002153815
MolPort-003-666-812
Multi-Relax
N,d]cycloheptene-.delta.,5.gamma.-propylamine, hydrochloride
N,d]cycloheptene-.delta.(sup5,.gamma.)-propylamine hydrochloride
N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Delta(5,gamma)-propylamine hydrochloride
N,N-Dimethyl-5H-dibenzo(a,d)cycloheptene-delta(sup 5,gamma)-propylamine hydrochloride
NCGC00013841-01
NCGC00013841-09
NCGC00093752-01
NCGC00093752-02
NCGC00093752-03
NCGC00093752-04
NCGC00093752-05
NCGC00095017-01
NCGC00095017-02
NCGC00095017-03
NCGC00095017-04
NCGC00260988-01
Novo-Cycloprine
NSC 169900
NSC 173379
NSC 78206
NSC-169900
NSC-173379
NSC-758414
NSC-78206
NSC169900
NSC173379
NSC758414
NSC78206
Pharmakon1600-01503207
PL053563
Prestwick_790
Proheptatrien monohydrochloride
Proheptatriene hydrochloride
Proheptatriene monohydrochloride
PubChem15660
PubChem18912
Q517
s4283
SC-18388
SCHEMBL41376
SMR000326702
SPECTRUM1503207
SR-01000075761
SR-01000075761-1
ST24041508
ST51054170
Tabradol
Tensodox
TNX-102
TNX-102 SL
TNX-105
Tonmya
Tox21_110040
Tox21_110040_1
Tox21_500303
UNII-0VE05JYS2P
VXEAYBOGHINOKW-UHFFFAOYSA-N
W-105056
WLN: L C676 BHJ B3N1&1 &GH
Tentative approvals for CYCLOBENZAPRINE HYDROCHLORIDE
Applicant Application No. Strength Dosage Form
➤ Sign Up➤ Sign Up15MGCAPSULE, EXTENDED RELEASE; ORAL
➤ Sign Up➤ Sign Up30MGCAPSULE, EXTENDED RELEASE; ORAL

US Patents and Regulatory Information for cyclobenzaprine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orit Labs Llc CYCLOBENZAPRINE HYDROCHLORIDE cyclobenzaprine hydrochloride TABLET;ORAL 078218-002 Jun 19, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Rubicon Res Pvt Ltd CYCLOBENZAPRINE HYDROCHLORIDE cyclobenzaprine hydrochloride TABLET;ORAL 208170-002 May 31, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Kvk Tech CYCLOBENZAPRINE HYDROCHLORIDE cyclobenzaprine hydrochloride TABLET;ORAL 078048-001 Feb 28, 2011 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for cyclobenzaprine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Res And Dev FLEXERIL cyclobenzaprine hydrochloride TABLET;ORAL 017821-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Janssen Res And Dev FLEXERIL cyclobenzaprine hydrochloride TABLET;ORAL 017821-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Janssen Res And Dev FLEXERIL cyclobenzaprine hydrochloride TABLET;ORAL 017821-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Janssen Res And Dev FLEXERIL cyclobenzaprine hydrochloride TABLET;ORAL 017821-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for cyclobenzaprine hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,877,245 Modified release dosage forms of skeletal muscle relaxants ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Deloitte
Boehringer Ingelheim
Accenture
Moodys
Chinese Patent Office
Covington
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.